ArticleACS applied materials & interfaces2025
Physicochemical Design of Nanoparticles to Interface with and Degrade Neutrophil Extracellular Traps.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Engineered immune-driven theranostics for clinical cardiology.Military Medical Research · 2025Review
- Advanced Nanoparticle Therapeutics for Targeting Neutrophils in Inflammatory Diseases.Advanced healthcare materials · 2025Review
- NETs - as predictors and targets of supportive therapy for cancer treatment.Frontiers in immunology · 2025Review
- From "immune silence" to "immune dialogue": modification strategies for bone substitutes based on bone immunomodulatory characteristics.Frontiers in cell and developmental biology · 2025Review
- Extracellular Trap-Related Genes as Potential Diagnostic Biomarkers for Endometriosis.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neutrophil extracellular traps (NETs) are networks of decondensed chromatin, histones, and antimicrobial proteins released by neutrophils in response to an infection. NET overproduction can cause an exacerbated hyperinflammatory response in a variety of diseases and can lead to host tissue damage without clearance of infection. Nanoparticle drug delivery is a promising avenue for creating materials that can both target NETs and deliver sustained amounts of NET-degrading drugs to alleviate hyperinflammation. Here, we study how particle physicochemical properties can influence NET interaction and leverage our findings to create NET-interfacing and NET-degrading particles. We fabricated a panel of particles of varying sizes (200 to 1000 nm) and charges (positive, neutral, negative) and found that positive charge is the main driver of NET-particle interaction, with smaller 200 nm positive particles having a 10-fold increase in binding compared to larger 1000 nm positive particles. Negative and neutral particles were mostly noninteracting, except for small negatively charged particles that exhibited very low levels of NET localization. Interaction strength of particles with NETs was quantified via shear flow assays and atomic force microscopy. This information was leveraged to create DNase-loaded particles that could adhere to NETs at varying degrees and therefore degrade NETs at different rates
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.